| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -71,600 | -70,200 |
| Depreciation and amortization | 29,000 | 19,600 |
| Stock-based compensation expense | 11,400 | 7,900 |
| Goodwill impairment | 77,000 | 77,000 |
| Net loss on asset dispositions | -5,700 | -300 |
| Accounts receivable | -22,800 | -22,100 |
| Inventories | 2,600 | 2,100 |
| Prepaid expenses and other assets | 1,600 | -2,200 |
| Accounts payable | -500 | -1,600 |
| Accrued expenses | -22,400 | -22,000 |
| Deferred income taxes and other | -700 | -700 |
| Cash provided by operating activities | 46,500 | 32,500 |
| Capital expenditures | 24,700 | 17,700 |
| Proceeds from the sale of assets | 4,000 | - |
| Proceeds from rh divestiture post-closing settlement | 0 | 0 |
| Acquisition of assets and investments in businesses | -28,300 | - |
| Investments in non-affiliates | 4,800 | 4,600 |
| Cash used in investing activities | -53,800 | -22,300 |
| Secured debt repayments | 7,000 | 4,700 |
| Revolving credit facility proceeds | 0 | 0 |
| Revolving credit facility repayments | 25,000 | 25,000 |
| Purchases of treasury stock | 3,000 | 3,000 |
| Proceeds from the exercise of stock options | 700 | 400 |
| Payment of contingent consideration liabilities | 0 | 0 |
| Cash used in financing activities | -34,300 | -32,300 |
| Effect of exchange rate changes on cash and cash equivalents | 4,400 | 4,700 |
| (decrease) increase in cash and cash equivalents | -37,200 | -17,400 |
| Cash and cash equivalents at beginning of period | 107,700 | - |
| Cash and cash equivalents at end of period | 70,500 | - |
AVANOS MEDICAL, INC. (AVNS)
AVANOS MEDICAL, INC. (AVNS)